Winner Medical Co., Ltd.: history, ownership, mission, how it works & makes money

From a Shenzhen workshop in 1991 to a Shenzhen Stock Exchange relisting in September 2020 under ticker 300888, Winner Medical's story blends entrepreneurial grit and global expansion: founded by Li Jianquan-who today holds a controlling 68% stake-the company navigated U.S. listings (OTCBB, AMEX, NASDAQ), a privatization move in 2012 for CNY 109.7 million, and now shows a market capitalization of about CNY 23.10 billion (EV CNY 22.78 billion) as of November 14, 2025; with 582.33 million shares outstanding and insiders owning 70.43%, Winner leans on two core segments-Medical Consumables and Consumer Goods-selling wound care, surgical disposables, incontinence and baby-care products under Winner Medical, Purcotton and PureH2B across roughly 110 countries, supported by a robust distributor network; financials underline momentum with CNY 8.98 billion revenue in 2024 (+9.69% YoY), a trailing P/E of 26.47 (forward 22.18), heavy innovation (1,375 patents: 140 invention, 810 utility model, 425 design) and sustained R&D investment (~6.5% of revenue in 2022), while projected revenues point to growth toward CNY 11.187 billion in 2025 and CNY 12.594 billion in 2026-details that make a deeper dive into Winner's history, ownership, mission, operations and monetization well worth reading.

Winner Medical Co., Ltd. (300888.SZ): Intro

• Founder: Li Jianquan - established the company in Shenzhen in 1991.
• Core product categories: wound dressings, ostomy supplies, NPWT consumables, surgical disposables, infection-control consumables.
• Primary markets: domestic China hospitals and retail, export markets including North America, Europe, Asia-Pacific.

• Product sales - majority of revenue generated from the manufacture and sale of single-use medical devices (wound care dressings, ostomy systems, NPWT consumables, surgical consumables).
• OEM/ODM manufacturing - contract manufacturing for domestic and international medical brands and institutions.
• Export channels - international sales to distribution partners and hospitals; export-driven revenue contributes materially to total sales.
• Value-added services - product customization, integrated supply solutions for hospital procurement and institutional buyers.

• Major shareholder: Li Jianquan - controlling stake reported at approximately 68% at the time of the 2020 Shenzhen listing.
• Delisting & privatization history: controlled re-privatization in 2012 via Winner Holding Limited, enabling later relisting in China.

• Manufacturing network: multiple production facilities in China focused on high-volume disposable medical product manufacture and quality-controlled processes suited for export.
• R&D and product development: ongoing investment in wound-care technologies (including NPWT consumables) and sterile single-use solutions to expand product mix and margins.
• Channels: direct hospital procurement, distributors, retail/OTC (where applicable), and international distributors for exports.

Winner Medical Co., Ltd. (300888.SZ): History

• Established: 1990s (industrial start and gradual national expansion)
• Primary products: disposable wound dressings, bandages, protective medical supplies
• Growth drivers: manufacturing scale-up, international distribution, product R&D

• Stable capital structure: shares outstanding decreased by 0.69% year-over-year to 582.33M, reflecting minor buybacks or adjustments.
• Control: insiders hold a dominant 70.43% stake, indicating concentrated internal control and long-term alignment.
• External participation: institutional investors own 8.97%, suggesting moderate third-party investment interest.

Winner Medical Co., Ltd. (300888.SZ): Ownership Structure

• Core mission: protect lives, advance health, and expand accessible medical & personal care solutions.
• Strategic focus: innovation-led growth across medical & health care, personal care, home care, maternal & child care, home textiles and apparel.
• Sustainability: lifecycle material sourcing, waste reduction in production, and alignment with global environmental goals.
• Compliance & quality: ISO 13485, CE marking, and multiple FDA clearances for key products.

• Certifications and approvals: ISO 13485, CE, multiple FDA clearances - supporting exports and global market access.
• R&D scale: patents concentrated in wound care, surgical dressings, personal protective equipment and related materials - 140 invention patents underscore product innovation capacity.

• Product sales: primary revenue from medical consumables (wound care, dressings, surgical consumables) sold to hospitals, distributors and retailers.
• Diversified channels: domestic hospital procurement, online retail, export markets across Europe, North America and Asia.
• Value add: proprietary materials, design patents, scale manufacturing and regulatory approvals allow premium pricing on differentiated products.
• Adjacencies: growing contributions from personal care, home care and home textile/apparel segments broaden margins and reduce cyclicality.

Winner Medical Co., Ltd. (300888.SZ): Mission and Values

• Business segments: operates through two primary segments - Medical Consumables and Consumer Goods.
• Medical Consumables: includes wound care products (gauzes, bandages, adhesive and film dressings), hydrogel products, advanced antibacterial dressings, and surgical consumables for clinical use.
• Consumer Goods: comprises personal care lines such as incontinence products, foot and daily care items, cosmetics, sanitary napkins, baby diapers, and other hygiene products under consumer-oriented brands.
• Brands and channels: distributes under Winner Medical, Purcotton, and PureH2B via direct sales teams, hospitals and healthcare institutions, e‑commerce platforms, pharmacies, and retail/chain stores.
• Global reach: exports to roughly 110 countries and regions, serving hospitals, retailers, and households worldwide.
• R&D focus: invested about 6.5% of 2022 revenue into research and development, leading to proprietary technologies like Hydrogel formulations and advanced antibacterial dressings.

• Medical Consumables: ~70% of revenue - ≈ RMB 4.886 billion (clinical wound care, surgical disposables).
• Consumer Goods: ~30% of revenue - ≈ RMB 2.094 billion (Purcotton, PureH2B household and personal care products).

• Product sales: primary revenue from manufacturing and selling medical dressings, surgical disposables, and consumer hygiene products.
• Channel diversification: revenues from institutional contracts (hospitals, clinics), retail chains, pharmacy networks, and e‑commerce marketplaces.
• Export sales: significant contribution from international markets across Asia, Europe, Americas, Africa and Oceania.
• Value‑added solutions: higher‑margin proprietary products (e.g., Hydrogel and antibacterial dressings) and branded consumer lines drive margin expansion.
• R&D-driven differentiation: sustained R&D investment (6.5% of 2022 revenue) supports product innovation and premium pricing.

• R&D intensity: ~6.5% of revenue allocated to R&D in 2022, enabling development of Hydrogel technology and advanced antibacterial dressing lines.
• IP and product pipeline: proprietary formulations and manufacturing know‑how support clinical performance claims and reimbursement access.
• Quality and compliance: manufacturing certifications and regulatory registrations in multiple markets facilitate exports and institutional procurement.

Winner Medical Co., Ltd. (300888.SZ): How It Works

• Primary revenue drivers: sale of medical consumables (wound care, surgical consumables) and consumer goods (wet/dry cotton towels, sanitary napkins, adult apparel).
• Distribution model: direct sales to hospitals and clinics, partnerships with national and regional distributors, and international distributors covering retail and institutional channels in 60+ countries.
• R&D and product pipeline: in-house research centers and collaboration with clinical partners to develop higher-margin, differentiated products that extend product lifecycles and open new markets.

• Manufacturing scale lowers unit cost - large production facilities and automated lines reduce COGS for high-volume consumables.
• Product mix management - higher-margin proprietary wound-care products and innovative disposables shift revenue composition upward.
• Channel leverage - institutional contracts (hospitals/clinics) provide recurring bulk orders while retail consumer goods broaden market exposure and stabilize seasonal demand.
• Export growth - international distributor partnerships increase volume and diversify market risk across >60 countries.
• R&D-driven pricing power - new and improved products support premium pricing and differentiated market positions.

Winner Medical Co., Ltd. (300888.SZ): How It Makes Money

• Market capitalization: CNY 23.10 billion (as of 2025-11-14)
• Trailing P/E: 26.47; Forward P/E: 22.18
• Global reach: products sold in 60+ countries via distributors and partners
• Intellectual property: 1,375 total patents (140 invention, 810 utility model, 425 design)

• Wound care dressings and advanced wound management products - core branded revenue and hospital tenders
• Disposable medical devices (catheters, protective gear) - high-volume export sales and contracts
• Orthopedic and rehabilitation consumables - growing clinical adoption
• OEM/ODM manufacturing for international medical companies - steady contract revenue and utilization of production capacity
• Aftermarket/service and technical support for clinical users - recurring revenue and customer retention